Samuel C. Kim

From probe to prodrug: immunoproteasome activity as a trigger for disease-selective therapeutics

Developing novel strategies that can exploit a cell's endogenous machinery to selectively release toxic compounds in diseased cells, while leaving healthy cells unaffected, is a challenging task to accomplish. An established approach involves antigen recognition on tumor cells, enabling targeted delivery of prodrugs in...